GLPwatch
MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice.
Clin Invest Med · 2018
Last updated 2026-05-28In a 13-week study, mice fed a high-fat diet and given the GLP-1 drug Exendin-4 at doses of 3 or 30 micrograms per kilogram per day lost weight and ate less. The treatment also improved measures of blood sugar control and insulin resistance compared to untreated mice.
AI summary of the abstract below.
| Journal | Clin Invest Med, 2018 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 0.35 |
| NIH percentile | 21 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
PURPOSE: The purpose of this study was to test whether glucagon-like peptide-1 (GLP-1) receptor activation preserved pancreatic β-cells via the regulation of microRNAs and target genes in high-fat-diet-fed mice.
METHODS: C57BL/6 male mice were simultaneously treated with high-fat-diet (HFD) and GLP-1 analogue, Exendin-4 (Ex-4) (3 μg/kg/day or 30 μg/kg/day), i.p. or vehicle, for consecutive 13 weeks. Fasting blood glucose, postprandial blood glucose, ΔI30/ΔG30, HOMA-IR and HOMA-% β were measured in each group. Pancreatic β-cell mass was assessed by immunohistochemistry. The expression of miRNAs and related downstream genes were investigated using quantitative real-time PCR.
RESULTS: Thirteen weeks of Ex-4 treatment significantly reduced body weight and food intake in HFD-fed mice (P.
Verbatim abstract via PubMed 29603687 ↗